Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure

Andreas Luchner, Tracy L. Stevens, Daniel Dean Borgeson, Margaret May Redfield, Chi Ming Wei, J. Gordon Porter, John C Jr. Burnett

Research output: Contribution to journalArticle

Abstract

Although brain natriuretic peptide (BNP) of myocardial origin is important in cardiovascular and renal function and as a marker of cardiac dysfunction, the expression of BNP in atrial and ventricular myocardium remains controversial both under normal conditions and in heart failure. We therefore determined left atrial and left ventricular (LV) gene expression and tissue concentration as well as circulating BNP during the evolution of rapid ventricular pacing-induced congestive heart failure (CHF) in the dog. Early LV dysfunction after 10 days of pacing was characterized by impaired LV function but maintained arterial pressure, and overt CHF after 38 days of pacing was characterized by further impaired LV function and decreased systemic arterial pressure. Under normal conditions, cardiac BNP mRNA and cardiac tissue BNP were of atrial origin. In early LV dysfunction, BNP mRNA and tissue BNP were markedly increased in the left atrium in association with an increase in circulating BNP but remained below or at the limit of detection in the LV. In overt CHF, BNP mRNA was further increased in the left atrium and first increased in the LV, together with an increase in LV tissue BNP and a further increase in circulating BNP. In the progression of CHF, early LV dysfunction is characterized by a selective increase in atrial BNP expression in association with increased circulating BNP. Overt CHF is characterized by an additional recruitment of ventricular BNP expression and a further increase in circulating BNP. These studies provide important new insight into the local and temporal regulation of cardiac BNP gene expression during the progression of heart failure and underscore the predominant endocrine role of atrial myocardium under normal conditions and in early LV dysfunction.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume274
Issue number5 43-5
StatePublished - May 1998

Fingerprint

Brain Natriuretic Peptide
Heart Failure
Left Ventricular Dysfunction
Heart Atria
Left Ventricular Function
Messenger RNA
Myocardium
Arterial Pressure
Gene Expression
Atrial Natriuretic Factor

Keywords

  • Brain natriuretic peptide
  • Gene expression
  • Natriuretic peptides
  • Progressive heart failure

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. / Luchner, Andreas; Stevens, Tracy L.; Borgeson, Daniel Dean; Redfield, Margaret May; Wei, Chi Ming; Porter, J. Gordon; Burnett, John C Jr.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 274, No. 5 43-5, 05.1998.

Research output: Contribution to journalArticle

@article{cd795f6fb3a44401b271cda5259c445d,
title = "Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure",
abstract = "Although brain natriuretic peptide (BNP) of myocardial origin is important in cardiovascular and renal function and as a marker of cardiac dysfunction, the expression of BNP in atrial and ventricular myocardium remains controversial both under normal conditions and in heart failure. We therefore determined left atrial and left ventricular (LV) gene expression and tissue concentration as well as circulating BNP during the evolution of rapid ventricular pacing-induced congestive heart failure (CHF) in the dog. Early LV dysfunction after 10 days of pacing was characterized by impaired LV function but maintained arterial pressure, and overt CHF after 38 days of pacing was characterized by further impaired LV function and decreased systemic arterial pressure. Under normal conditions, cardiac BNP mRNA and cardiac tissue BNP were of atrial origin. In early LV dysfunction, BNP mRNA and tissue BNP were markedly increased in the left atrium in association with an increase in circulating BNP but remained below or at the limit of detection in the LV. In overt CHF, BNP mRNA was further increased in the left atrium and first increased in the LV, together with an increase in LV tissue BNP and a further increase in circulating BNP. In the progression of CHF, early LV dysfunction is characterized by a selective increase in atrial BNP expression in association with increased circulating BNP. Overt CHF is characterized by an additional recruitment of ventricular BNP expression and a further increase in circulating BNP. These studies provide important new insight into the local and temporal regulation of cardiac BNP gene expression during the progression of heart failure and underscore the predominant endocrine role of atrial myocardium under normal conditions and in early LV dysfunction.",
keywords = "Brain natriuretic peptide, Gene expression, Natriuretic peptides, Progressive heart failure",
author = "Andreas Luchner and Stevens, {Tracy L.} and Borgeson, {Daniel Dean} and Redfield, {Margaret May} and Wei, {Chi Ming} and Porter, {J. Gordon} and Burnett, {John C Jr.}",
year = "1998",
month = "5",
language = "English (US)",
volume = "274",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "5 43-5",

}

TY - JOUR

T1 - Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure

AU - Luchner, Andreas

AU - Stevens, Tracy L.

AU - Borgeson, Daniel Dean

AU - Redfield, Margaret May

AU - Wei, Chi Ming

AU - Porter, J. Gordon

AU - Burnett, John C Jr.

PY - 1998/5

Y1 - 1998/5

N2 - Although brain natriuretic peptide (BNP) of myocardial origin is important in cardiovascular and renal function and as a marker of cardiac dysfunction, the expression of BNP in atrial and ventricular myocardium remains controversial both under normal conditions and in heart failure. We therefore determined left atrial and left ventricular (LV) gene expression and tissue concentration as well as circulating BNP during the evolution of rapid ventricular pacing-induced congestive heart failure (CHF) in the dog. Early LV dysfunction after 10 days of pacing was characterized by impaired LV function but maintained arterial pressure, and overt CHF after 38 days of pacing was characterized by further impaired LV function and decreased systemic arterial pressure. Under normal conditions, cardiac BNP mRNA and cardiac tissue BNP were of atrial origin. In early LV dysfunction, BNP mRNA and tissue BNP were markedly increased in the left atrium in association with an increase in circulating BNP but remained below or at the limit of detection in the LV. In overt CHF, BNP mRNA was further increased in the left atrium and first increased in the LV, together with an increase in LV tissue BNP and a further increase in circulating BNP. In the progression of CHF, early LV dysfunction is characterized by a selective increase in atrial BNP expression in association with increased circulating BNP. Overt CHF is characterized by an additional recruitment of ventricular BNP expression and a further increase in circulating BNP. These studies provide important new insight into the local and temporal regulation of cardiac BNP gene expression during the progression of heart failure and underscore the predominant endocrine role of atrial myocardium under normal conditions and in early LV dysfunction.

AB - Although brain natriuretic peptide (BNP) of myocardial origin is important in cardiovascular and renal function and as a marker of cardiac dysfunction, the expression of BNP in atrial and ventricular myocardium remains controversial both under normal conditions and in heart failure. We therefore determined left atrial and left ventricular (LV) gene expression and tissue concentration as well as circulating BNP during the evolution of rapid ventricular pacing-induced congestive heart failure (CHF) in the dog. Early LV dysfunction after 10 days of pacing was characterized by impaired LV function but maintained arterial pressure, and overt CHF after 38 days of pacing was characterized by further impaired LV function and decreased systemic arterial pressure. Under normal conditions, cardiac BNP mRNA and cardiac tissue BNP were of atrial origin. In early LV dysfunction, BNP mRNA and tissue BNP were markedly increased in the left atrium in association with an increase in circulating BNP but remained below or at the limit of detection in the LV. In overt CHF, BNP mRNA was further increased in the left atrium and first increased in the LV, together with an increase in LV tissue BNP and a further increase in circulating BNP. In the progression of CHF, early LV dysfunction is characterized by a selective increase in atrial BNP expression in association with increased circulating BNP. Overt CHF is characterized by an additional recruitment of ventricular BNP expression and a further increase in circulating BNP. These studies provide important new insight into the local and temporal regulation of cardiac BNP gene expression during the progression of heart failure and underscore the predominant endocrine role of atrial myocardium under normal conditions and in early LV dysfunction.

KW - Brain natriuretic peptide

KW - Gene expression

KW - Natriuretic peptides

KW - Progressive heart failure

UR - http://www.scopus.com/inward/record.url?scp=0031835264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031835264&partnerID=8YFLogxK

M3 - Article

C2 - 9612380

VL - 274

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 5 43-5

ER -